The generic name for Xiidra is lifitegrast [1]. Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease [1].
When is Lifitegrast Expected to Go Generic?
The patent for Xiidra (lifitegrast) is set to expire in the coming years. According to DrugPatentWatch.com, the last-to-expire patent for lifitegrast is anticipated to expire in 2030 [2]. This patent expiration date is crucial for understanding when generic versions of the drug may become available.
What is Lifitegrast Used For?
Lifitegrast is indicated for the treatment of the signs and symptoms of dry eye disease [1]. It works by targeting underlying inflammation associated with the condition.
How Does Lifitegrast Work?
Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist [1]. By blocking the interaction between LFA-1 and intercellular adhesion molecule-1 (ICAM-1), it is believed to reduce inflammation in the eyes that contributes to dry eye disease.
What Are the Side Effects of Lifitegrast?
Common side effects reported with lifitegrast include eye irritation, discomfort, and changes in taste sensation [1]. Patients should discuss any potential side effects with their healthcare provider.
Are There Alternatives to Lifitegrast for Dry Eye?
Several other treatments are available for dry eye disease, including artificial tears, other prescription eye drops like cyclosporine, punctal plugs, and lifestyle adjustments [3]. The choice of treatment depends on the severity and underlying cause of the dry eye.
---
Sources:
1. https://www.rxlist.com/xiidra-drug-f.htm
2. https://drugpatentwatch.com/
3. https://www.mayoclinic.org/diseases-conditions/dry-eyes/diagnosis-treatment/drc-20371863